Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$144.19B | 25.5x | 0.69 | HK$23.90 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.3% Upside | Upgrade to Pro+ | |
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$89.25B | -850.8x | -8.51 | HK$54.35 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$71.85B | 14.8x | 0.65 | HK$10.78 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.2% Upside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$70.50B | 37x | 0.62 | HK$3.95 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.1% Upside | Upgrade to Pro+ | |
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$70.24B | 15.5x | -0.54 | HK$6.11 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.2% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$68.11B | 23.3x | 1.29 | HK$14.84 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.1% Upside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$54.42B | 7.3x | -0.33 | HK$17.42 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.4% Upside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$45B | 14.9x | -0.47 | HK$16.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.1% Upside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$44.24B | 45x | 0.15 | HK$37.15 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.4% Upside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$30.97B | 8.7x | -0.64 | HK$4.92 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.8% Upside | Upgrade to Pro+ | |
3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$30.60B | 14.4x | 0.35 | HK$13.02 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -8.7% Downside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$28.80B | -13.6x | -0.49 | HK$25.65 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.2% Upside | Upgrade to Pro+ | |
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$28.11B | 23.7x | -0.42 | HK$50.65 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
Shanghai Junshi Biosciences | Hong Kong | Healthcare | Pharmaceuticals | HK$28.01B | -10.5x | -0.44 | HK$15.42 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.2% Upside | Upgrade to Pro+ | |
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$25.07B | 8.9x | -5.32 | HK$13.82 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.3% Upside | Upgrade to Pro+ | |
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$23.66B | 15x | 2.02 | HK$26.70 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.4% Upside | Upgrade to Pro+ | |
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$21.78B | 25.8x | 3.28 | HK$8.53 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.1% Upside | Upgrade to Pro+ | |
Henlius Biotech | Hong Kong | Healthcare | Pharmaceuticals | HK$21.17B | 20x | 0.41 | HK$37.85 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -10.7% Downside | Upgrade to Pro+ | |
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$20.54B | 12.1x | -0.32 | HK$8.53 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.9% Upside | Upgrade to Pro+ | |
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$20.45B | 8.4x | 0.25 | HK$5.86 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21% Upside | Upgrade to Pro+ | |
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$20.38B | 76.8x | -0.96 | HK$23.40 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$17.01B | 24.8x | 0.12 | HK$4.39 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -13.8% Downside | Upgrade to Pro+ | |
Yichang Hec Changjiang Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$11.03B | 21.3x | -0.27 | HK$12.20 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.3% Upside | Upgrade to Pro+ | |
Cansino Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$10.78B | -22.7x | -0.35 | HK$30.80 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.8% Upside | Upgrade to Pro+ | |
China Traditional Chinese Medicine | Hong Kong | Healthcare | Pharmaceuticals | HK$10.22B | 192.5x | -1.77 | HK$2.04 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -15.7% Downside | Upgrade to Pro+ | |
SSY Group | Hong Kong | Healthcare | Pharmaceuticals | HK$8.85B | 8.4x | -0.43 | HK$3.01 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Consun Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$7.91B | 8.1x | 0.72 | HK$9.52 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.1% Upside | Upgrade to Pro+ | |
Luye Pharma Group | Hong Kong | Healthcare | Pharmaceuticals | HK$7.56B | 14.6x | -1.17 | HK$2 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.5% Upside | Upgrade to Pro+ | |
Beijing Tong Ren Tang | Hong Kong | Healthcare | Pharmaceuticals | HK$7.20B | 14.4x | -1.91 | HK$8.59 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.6% Upside | Upgrade to Pro+ | |
Shanghai Fudan-Zhangjiang Bio-Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$6.74B | 61.4x | -2.45 | HK$2.44 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hbm | Hong Kong | Healthcare | Pharmaceuticals | HK$6.37B | 281.3x | -3.19 | HK$8.21 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tong Ren Tang Tech | Hong Kong | Healthcare | Pharmaceuticals | HK$6.10B | 10.9x | -0.93 | HK$4.78 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.8% Upside | Upgrade to Pro+ | |
Sihuan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$6.07B | -30.5x | 0.08 | HK$0.66 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascletis Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$6.01B | -19.7x | 0.12 | HK$6.28 | -6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -27.3% Downside | Upgrade to Pro+ | |
China Shineway Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$5.83B | 6.6x | -0.48 | HK$7.74 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.3% Upside | Upgrade to Pro+ | |
Shandong Boan Biotechnology | Hong Kong | Healthcare | Pharmaceuticals | HK$5.70B | 55.8x | 0.6 | HK$10.58 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.6% Downside | Upgrade to Pro+ | |
Beijing Luzhu Biotechnology | Hong Kong | Healthcare | Pharmaceuticals | HK$4.96B | -27.9x | -0.83 | HK$24.50 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.9% Upside | Upgrade to Pro+ | |
Ocumension | Hong Kong | Healthcare | Pharmaceuticals | HK$4.50B | -12x | -0.41 | HK$5.52 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.4% Upside | Upgrade to Pro+ | |
AIM Vaccine | Hong Kong | Healthcare | Pharmaceuticals | HK$4.16B | -16.9x | -0.17 | HK$3.29 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shandong Xinhua Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$3.74B | 20.5x | -3.03 | HK$5.63 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
VIVA Biotech Holdings | Hong Kong | Healthcare | Pharmaceuticals | HK$3.19B | 27.9x | 0.11 | HK$1.48 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Golden Throat | Hong Kong | Healthcare | Pharmaceuticals | HK$3.10B | 9.1x | 0.33 | HK$4.19 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shanghai Pioneer Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$2.63B | 16.3x | 3.02 | HK$2.26 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Essex Bio-Tech | Hong Kong | Healthcare | Pharmaceuticals | HK$2.49B | 9.1x | 0.56 | HK$4.38 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Everest Med | Hong Kong | Healthcare | Pharmaceuticals | HK$2.44B | -16.4x | 0.68 | HK$47.40 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jacobson Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$2.42B | 9.5x | -1.17 | HK$1.23 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cutia Therapeutics | Hong Kong | Healthcare | Pharmaceuticals | HK$1.85B | -3.9x | -0.04 | HK$5.68 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jbm | Hong Kong | Healthcare | Pharmaceuticals | HK$1.80B | 10.7x | 0.13 | HK$2.26 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.5% Upside | Upgrade to Pro+ | |
Dawnrays Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$1.74B | 2.9x | 0.04 | HK$1.16 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beijing Biostar Pharmaceuticals | Hong Kong | Healthcare | Pharmaceuticals | HK$1.61B | -26.6x | HK$4.41 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |